title: Efficacy and tolerability assessment of cefprozil in children with acute otitis media.
abstract: Young children contract as many as six to eight upper respiratory tract viral infections per year, and these infections frequently lead to secondary bacterial infections such as acute otitis media and sinusitis. Cefprozil is an orally active third generation cephalosporin which has demonstrated activity against the gram-positive organisms Streptococcus pyogenes, pneumoniae and agalactiae and against methicilin-susceptible Staphylococcus aureus. Cefprozil is also active against various gram-ves and certain anaerobic organisms, and is stable to hydrolysis by a number of b-lactamases. Present study is an effort to study the efficacy and safety of cefprozil in children with acute otitis media. Three hundred and thirty four children aged 6 months through 12 years with clinical symptoms and tympanic membrane signs of AOM received cefprozil 30 mg/kg/day in two divided doses per day for 10 days. Clinically, 96.6% patients were cured, 2.4% improved and there was failure of therapy in 1% of the patients. There was no need for any rescue medication and any change in antibiotic in any patient. A satisfactory bacteriological outcome was (i.e. cure, presumed cure, and cure plus reinfection with a different pathogen) was achieved in 95% of patients. In conclusion, cefprozil is a well tolerated and effective drug for acute otitis media in children. Moreover, its expanded spectrum of activity, ability to achieve adequate concentrations in tissues, suitability for twice-daily dosing, and proven tolerability suggest that it is a better alternative to agents conventionally used in acute otitis media.
authors.affiliation: Department of Pediatrics, Batra Hospital & Research Centre, New Delhi, India.
authors.forename: Nomeeta
authors.initials: N
authors.lastname: Gupta
authors.forename: Vivek
authors.initials: V
authors.lastname: Bagga
authors.forename: Bharat J
authors.initials: BJ
authors.lastname: Parmar
authors.forename: Kishaloy
authors.initials: K
authors.lastname: Kar
authors.forename: Abhijit
authors.initials: A
authors.lastname: Mukherjee
authors.forename: Sandip
authors.initials: S
authors.lastname: Mehta
authors.forename: Ashok K
authors.initials: AK
authors.lastname: Moharana
mesh_terms: D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome; D000097670:Cefprozil
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097670:Cefprozil